He doesn't control the share price? Sure they could have engaged better with shareholders, but I actually think he has performed incredibly well, surely people here also have experience of companies that do nothing but bleed shareholders for cash? Under Wolgen's leadership this company was brought from literally nothing to a market leader in melanocortins with a monopoly position, delivering strong and growing sales and cash flows. Sure the past few years haven't been that great (share price wise only, fundamentally it has been great), but he's been here a lot longer than 5 years and the share price has done very well over a longer time frame. I did expect this news but I'm very glad we got it, as I do indeed believe that he is best suited to make this a household name by 2026. I do firmly believe that so long as they continue to deliver on the fundamentals, the share price will eventually take care of itself.
- Forums
- ASX - By Stock
- Ann: CLINUVEL extends Managing Director Employment Agreement
He doesn't control the share price? Sure they could have...
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.09 |
Change
0.100(0.71%) |
Mkt cap ! $705.3M |
Open | High | Low | Value | Volume |
$14.00 | $14.30 | $13.93 | $676.4K | 47.95K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 200 | $14.04 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.16 | 405 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 200 | 14.040 |
1 | 150 | 13.920 |
2 | 6000 | 13.900 |
1 | 527 | 13.890 |
2 | 728 | 13.850 |
Price($) | Vol. | No. |
---|---|---|
14.290 | 709 | 1 |
14.300 | 833 | 1 |
14.430 | 668 | 1 |
14.460 | 709 | 1 |
14.490 | 180 | 1 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
CUV (ASX) Chart |